VOQP Stock Overview
VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
VioQuest Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.000001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.99% |
| 5 Year Change | -99.99% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| VOQP | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | -1.7% | -2.6% |
| 1Y | n/a | 3.2% | 24.5% |
Return vs Industry: Insufficient data to determine how VOQP performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how VOQP performed against the US Market.
Price Volatility
| VOQP volatility | |
|---|---|
| VOQP Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: VOQP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine VOQP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | n/a | n/a |
VioQuest Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of clinical stage drug therapies for the treatment of oncology and infectious diseases. Its lead product includes Xyfid, which is under development for the treatment and prevention of hand-foot syndrome. The company’s products also consist of VQD-002, a nucleoside analog that is in Phase I clinical trials for the treatment of cancer; and Lenocta, a small molecule inhibitor of various protein tyrosine phosphatases, which is in Phase IIa clinical trials for the treatment of melanoma, renal cell carcinoma, and other solid tumors.
VioQuest Pharmaceuticals, Inc. Fundamentals Summary
| VOQP fundamental statistics | |
|---|---|
| Market cap | US$6.00 |
| Earnings (TTM) | -US$11.15m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio0.0x
P/E RatioIs VOQP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VOQP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$11.15m |
| Earnings | -US$11.15m |
Last Reported Earnings
Jun 30, 2008
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did VOQP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/02/28 19:52 |
| End of Day Share Price | 2023/12/01 00:00 |
| Earnings | 2008/06/30 |
| Annual Earnings | 2007/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
VioQuest Pharmaceuticals, Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|